Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

465.96 +0.07 (+0.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,545,064
Open 466.29
Bid (Size) 462.13 (1)
Ask (Size) 476.00 (1)
Prev. Close 465.89
Today's Range 463.82 - 472.66
52wk Range 340.83 - 510.63
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best Biotech Stocks to Buy in August 2024
These biotech stocks are leading the way with groundbreaking therapies and robust fundamentals offering superb upside ahead. 
Via InvestorPlace
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire

Performance

YTD
+13.40%
+13.40%
1 Month
-4.12%
-4.12%
3 Month
+11.21%
+11.21%
6 Month
+10.14%
+10.14%
1 Year
+35.02%
+35.02%

More News

Read More
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Via The Motley Fool
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Via InvestorPlace
Vertex Slumps On Light Second-Quarter Despite Hiked 2024 Outlook
Via Investor's Business Daily
14 Analysts Assess Vertex Pharmaceuticals: What You Need To Know
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
Via The Motley Fool
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
Via The Motley Fool
3 Biotech Stocks That Could Have Investors Grinning Soon
Via InvestorPlace
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Via Benzinga
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Reports Second Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever
Via The Motley Fool
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Via Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
Via InvestorPlace
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Via Benzinga
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
Via The Motley Fool
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
Via InvestorPlace
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.